---
title: "Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295536384.md"
description: "Theriva Biologics reported Q2 2026 results showing a narrowed net loss of $3.22M, up from $13.06M prior year. The company is advancing its oncology pipeline, including VCN-01 for pancreatic cancer, following positive FDA feedback. With limited cash runway, Theriva is pursuing partnerships, out-licensing, and ATM equity sales to fund clinical programs while pausing SYN-004 development."
datetime: "2026-08-11T12:21:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295536384.md)
  - [en](https://longbridge.com/en/news/295536384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295536384.md)
---

# Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary

Theriva Biologics, Inc. reported results for the 2026 quarter showing a narrower comprehensive loss and net loss versus the prior-year quarter as the company advances its oncology-focused pipeline and pursues funding and partnerships to support upcoming clinical programs.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($3.35M)

($11.74M)

71.5%

Net income²

($3.22M)

($13.06M)

75.4%

Diluted EPS³

($0.07)

($1.93)

96.4%

_¹ Reported as “Total comprehensive loss”. ² Reported as “Net Loss Attributable to Common Stockholders”. ³ Reported as “Diluted loss Per Share - Basic and Dilutive”._

**Business Highlights**

-   Regulatory progress: Positive FDA End-of-Phase 2 feedback supporting a Phase 3 design for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC) with an adaptive, repeat-dosing plan.
-   Clinical momentum: VIRAGE Phase 2b showed improved overall and progression-free survival with two VCN-01 doses; a follow-up study, VIRAGE2, was authorized to evaluate increased dosing frequency.
-   Strategic focus: Following the Theriva acquisition, the company has shifted priority to oncology programs, pausing SYN-004 development absent partner funding and pursuing out-licensing for SYN-020.
-   Data and translational signals: Published head-and-neck cancer (HNSCC) Phase 1 results demonstrated immune activation, PK/biomarker signals and potential resensitization to durvalumab.
-   Funding actions: Management notes limited cash runway and is pursuing partnerships, out-licensing and at-the-market (ATM) equity sales to fund prioritized clinical and manufacturing activities.

Original SEC Filing: Theriva Biologics, Inc. \[ TOVX \] - 10-Q - Aug. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TOVX.US](https://longbridge.com/en/quote/TOVX.US.md)

## Related News & Research

- [HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer Program](https://longbridge.com/en/news/295697080.md)
- [Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer](https://longbridge.com/en/news/295106175.md)
- [Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trial](https://longbridge.com/en/news/291928699.md)
- [Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses](https://longbridge.com/en/news/295534557.md)
- [Rakovina leverages AI to advance next‑generation cancer drug candidates](https://longbridge.com/en/news/280125815.md)